FBV indicates sunitinib response
نویسندگان
چکیده
منابع مشابه
Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma In Vivo with Susceptibility Contrast MRI.
Antiangiogenic therapy is efficacious in metastatic renal cell carcinoma (mRCC). However, the ability of antiangiogenic drugs to delay tumor progression and extend survival is limited, due to either innate or acquired drug resistance. Furthermore, there are currently no validated biomarkers that predict which mRCC patients will benefit from antiangiogenic therapy. Here, we exploit susceptibilit...
متن کاملSunitinib Induced Immune Thrombocytopenia
Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. It has several adverse reactions on multi organ systems including hematologic system. Although the neutropenia and thrombocytopenia commonly happens as Gra...
متن کاملTumor response to sunitinib malate observed in clear-cell sarcoma.
We report on a tumor response to sunitinib malate (SM) in a 46-year-old female patient with metastatic clear-cell sarcoma (CCS). The tumor appeared in December 2008, with two close lesions located to the soft tissues of the left knee. It was initially treated elsewhere with a marginal excision plus local–regional lymph node dissection, followed by radiation therapy on the primary tumor site. Th...
متن کاملComplete cerebral response with sunitinib for metastatic renal cell carcinoma.
Renal cell carcinoma (RCC) is a relatively rare cancer, representing 2–3% of the neoplasms in the adult population. Metastasis is in 30% of cases synchronous to the diagnosis of RCC. The most frequent common sites of metastasis include lung, liver, bone, brain and adrenal gland [1]. Brain metastasis from RCC is responsible for significant mortality [2]. RCC is characterized by the inactivation ...
متن کاملResponse to sunitinib malate in advanced alveolar soft part sarcoma.
PURPOSE Alveolar soft part sarcoma (ASPS) is a rare, chemoresistant soft tissue sarcoma. ASPS harbors the t(17-X) (p11.2;q25) translocation, resulting in the ASPACR1-TFE3 fusion protein, causing MET autophosphorylation and activation of downstream signaling. The tumor vascular pattern prompted us to use sunitinib malate (SM), a tyrosine kinase inhibitor with antiangiogenic properties. EXPERIM...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Urology
سال: 2017
ISSN: 1759-4812,1759-4820
DOI: 10.1038/nrurol.2017.101